Drug firm Lupin on Tuesday said it in alliance with Natco Pharma has received nod from the US health regulator to market generic Imatinib Mesylate tablets used for treatment of certain types of cancer.
The product is a generic version of Novartis Pharmaceuticals Corporation's Gleevec tablets in the same strengths, Lupin said in a filing to BSE.
Lupin and Natco Pharma have received final approval from the US Food and Drug Administration (USFDA) to market generic Imatinib Mesylate tablets, 100 mg and 400 mg, the filing said.
As per IQVIA MAT December 2018 data, Imatinib Mesylate tablets, 100 mg (base) and 400 mg (base), had annual sales of approximately USD 655 million in the US, Lupin said.
Shares of Lupin closed at Rs 784.75 per scrip on BSE, down 0.13 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app